CureVac SE has successfully defended its mRNA therapy patent against BioNTech SE at a European patent authority. This decision allows CureVac to continue with litigation in Germany, accusing BioNTech of patent infringement. This ongoing legal confrontation underscores the competitive landscape in the biotechnology sector, particularly concerning mRNA technology, which gained significant attention during the COVID-19 pandemic due to its use in vaccine development.
Further details on this development can be accessed through Law360.